1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSocial Determinants of Health (SDoH) and Quality of Care Contributors to Cancer Disparities in People with HIV (U01; Clinical Trial Optional) is sponsored by NIH. Intends to solicit applications investigating the role of SDoH in cancer disparities among people with HIV.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-CA-24-106: Notice of Intent to Publish a Notice of Funding Opportunity for Social Determinants of Health (SDoH) and Quality of Care Contributors to Cancer Disparities in People with HIV (U01; Clinical Trial Optional) Notice of Intent to Publish a Notice of Funding Opportunity for Social Determinants of Health (SDoH) and Quality of Care Contributors to Cancer Disparities in People with HIV (U01; Clinical Trial Optional) Estimated Publication Date of Notice of Funding Opportunity : First Estimated Application Due Date: Earliest Estimated Award Date: Earliest Estimated Start Date: National Cancer Institute ( NCI ) The National Cancer Institute (NCI) intends to publish a new Notice of Funding Opportunity (NOFO) to solicit applications seeking to better understand the role of social determinants of health (SDoH) in contributing to or exacerbating cancer disparities and inequalities for people with HIV (PWH) across the cancer care continuum.
The solicited applications may propose research investigating health disparities that span cancer control and health care delivery, spanning screening, diagnosis, treatment, quality of life, and survivorship.
The primary objectives of this initiative will be to increase the NCIs research portfolio investigating cancer disparities in PWH and to advance the understanding of the influence of SDoH, and how they may contribute to health disparities in PWH and cancer. For this NOFO, observational, interventional, and translational research studies are within scope.
This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations. The NOFO is expected to use the U01 mechanism with approximately three to four awards anticipated for each of three receipt dates. Clinical trials are optional.
The NOFO is expected to be published in fall 2024 with expected application due dates in winter 2025, 2026, and 2027. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.
Research Initiative Details People with HIV (PWH) have a higher incidence of certain cancers, less frequent use of proven screening tests, higher rates of advanced cancer diagnoses, and are less likely to receive cancer treatment compared to individuals without HIV.
These health disparities are often further amplified in PWH who are members of underserved and marginalized groups, including: low-socioeconomic groups, underrepresented racial/ethnic populations, and those who live in geographically isolated areas. Data shows that various factors contribute to these disparities including patient-driven, provider-driven, and health systems-related issues.
SDoH are the unfair and avoidable factors that influence health. This includes the conditions of the environment in which people are born, grow, live, learn, work, play, and age that impact health outcomes, and operate at multiple levels of influence.
Much of the research in this area has focused on the relationship between SDoH and HIV care outcomes; however, a good deal of the data describes associations between a single factor (e.g., poverty) and clinical outcomes. Since SDoH are complex, intersecting, and reinforcing, multilevel approaches are needed to fully understand the contributors to cancer disparities seen in PWH.
This Notice encourages investigators and teams with expertise and insights into cancer disparities and/or inequalities in cancer prevention and care of PWH to consider applying for this new NOFO.
The primary objectives of this U01 RFA are to advance the understanding of how SDoH contribute to disparities and inequalities in the prevention, diagnosis, treatment, quality of life, and survivorship outcomes of PWH and cancer, with an expectation that the research may inform future interventions.
Research investigating the impact of SDoH may have on multiple levels (e.g., individual, family, community, systems, and population levels), health-related social needs, and their influence on cancer-related disparities in PWH are in scope. Furthermore, expertise in both cancer and HIV should be evident within the research team.
Proposed research areas could include, but are not limited to: Research to better understand how multiple SDoH interact and contribute to health disparities in cancer prevention, diagnosis, treatment, quality of life, and survivorship outcomes in PWH; Research eliciting how individual level, provider-level, and system-level factors influence the quality of cancer-related clinical care, enrollment options in clinical trials, access to cancer screening and diagnostic interventions among PWH; Research identifying and testing strategies to address multilevel SDoH influences that contribute to disparities in the prevention, diagnosis, treatment, quality of life, and survivorship outcomes of PWH and cancer; and Research identifying and testing strategies to address health-related social needs at the individual level that contribute to disparities in the prevention, diagnosis, treatment, quality of care, and survivorship outcomes of PWH and cancer.
The presentation of this initiative to the NCI Board of Scientific Advisors (BSA) can be accessed at this link (at time frame 4:20): https://videocast. nih. gov/watch=54859 and the slides can be accessed at https://deainfo.
nci. nih. gov/advisory/joint/0624/Huppi.
pdf . Expected Number of Awards $500,000 direct costs per year Primary Assistance Listing Number(s) 93. 393, 93.
394, 93. 395, 93.
399 Anticipated Eligible Organizations Public/State Controlled Institution of Higher Education Private Institution of Higher Education Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education) For-Profit Organization (Other than Small Business) Indian/Native American Tribal Government (Federally Recognized) Independent school districts U.S. Territory or Possession Indian/Native American Tribal Government (Other than Federally Recognized) Eligible Agencies of the Federal Government Applications are not being solicited at this time.
Please direct all inquiries to: Rebecca Liddell Huppi, Ph. D. Office of HIV and AIDS Malignancy National Cancer Institute (NCI) Center for Cancer Health Equity National Cancer Institute (NCI) Weekly TOC for this Announcement NIH...
Turning Discovery Into Health ®
According to the current listing, eligibility includes: Public and private institutions of higher education, non-profit organizations, and other domestic entities. Confirm the full requirements in the official notice before applying.
Social Determinants of Health (SDoH) and Quality of Care Contributors to Cancer Disparities in People with HIV (U01; Clinical Trial Optional) is funded by NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article